Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Oral idarubicin (40 mg/m2 in 3–4 divided doses over 24 h every 21 days) was tested in a group of patients with drug-resistant ovarian carcinoma. None of 13 patients responded and the study was discontinued. Toxicity was acceptable, with neutropaenia being doselimiting. It seems unlikely that idarubicin has significant activity in this disease although phase II studies should ideally be conducted in less heavily pretreated patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Berman E, Wittes RE, Leyland-Jones B (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6069–6101

    Google Scholar 

  2. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653

    Google Scholar 

  3. Gruppo Interegionale Cooperativo Oncologico Ginecologia (1987) Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet II:353–359

    Google Scholar 

  4. Haroussean JL, Hurteloup P, Reiffers J (1987) Idarubicin in the treatment of relapsed or refractory acute myeloid leukaemia. Cancer Treat Rep 71:991–992

    Google Scholar 

  5. Hubbard SM, Barkes P, Young RC (1978) Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep 62:1375–1377

    Google Scholar 

  6. Martoni A, Pacciarini MA, Pannuti F (1985) Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 21:803–806

    Google Scholar 

  7. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE (1989) Ten year follow-up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223–229

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRC Medical Oncology Unit, Southampton General Hospital, Room CF99, S09 4XY, Southampton, UK

    Christopher J. Williams

Authors
  1. Christopher J. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, C.J. A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma. Cancer Chemother. Pharmacol. 25, 304–305 (1990). https://doi.org/10.1007/BF00684891

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00684891

Keywords

Search

Navigation